Commitments and Contingencies (Details Narrative)	3 Months Ended
	Mar. 31, 2021 USD ($)
Aldoxorubicin [Member]
Amount of milestone payment payable	$ 7,500,000
Milestone payment, description	We also have agreed to pay: commercially reasonable royalties based on a percentage of net sales (as defined in the agreement); a percentage of non-royalty sub-licensing income (as defined in the agreement); and milestones of $1 million for each additional final marketing approval that we obtain.
Arimoclomol [Member]
Amount of milestone payment payable	$ 3,650,000
Innovivel [Member]
Future earnout merger consideration	$ 18,300,000